Does pretreatment with statins improve clinical outcome after stroke? A pilot case-referent study

被引:61
作者
Jonsson, N [1 ]
Asplund, K [1 ]
机构
[1] Umea Univ Hosp, Dept Med, S-90185 Umea, Sweden
关键词
case-control studies; neuroprotection; statins; stroke outcome;
D O I
10.1161/01.STR.32.5.1112
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background and Purpose-In primary and secondary prevention trials, statins have been shown to reduce the risk of stroke. In addition to lipid lowering, statins have a number of antiatherothrombotic and neuroprotective properties. III a preliminary observational study, we explored whether clinical outcome is improved in patients who are on treatment with statins when stroke occurs. Methods-We conducted a population-based case-referent study of 25- to 74-year-old stroke patients with, for each case of a patient who was on statin treatment at the onset of stroke (n=125), 2 referent patients who were not treated with statins but were matched for age, gender, year of onset, and stroke subtype (n=250). Results-The unadjusted odds ratio for early discharge to home (versus late discharge or death) was 1.41 (95% CI 0.91 to 2.17) when patients on statin treatment were compared with referent stroke patients not on statins. Prognostic factors were, in general, more unfavorable among patients on statins. When this was adjusted for in a logistic regression model, the use of statins was a moderately strong but statistically nonsignificant predictor of discharge to home (multiple-adjusted odds ratio 1.42, 95% CI 0.90 to 2.22). Conclusions-The statistical power of this case-referent study was such that only large beneficial effects of statins in acute stroke could be confirmed. However, the observed trend, together with experimental observations, is interesting enough to warrant a more detailed analysis of the relationship between statins and stroke outcome.
引用
收藏
页码:1112 / 1115
页数:4
相关论文
共 16 条
[1]   MULTINATIONAL COMPARISONS OF STROKE EPIDEMIOLOGY - EVALUATION OF CASE ASCERTAINMENT IN THE WHO MONICA STROKE STUDY [J].
ASPLUND, K ;
BONITA, R ;
KUULASMAA, K ;
RAJAKANGAS, AM ;
FEIGIN, V ;
SCHAEDLICH, H ;
SUZUKI, K ;
THORVALDSEN, P ;
TUOMILEHTO, J .
STROKE, 1995, 26 (03) :355-360
[2]  
ASPLUND K, 1988, ACTA MED SCAND, P26
[3]   DISEASE-FREE INTERVALS AFTER PARTIAL ILEAL BYPASS IN PATIENTS WITH CORONARY HEART-DISEASE AND HYPERCHOLESTEROLEMIA - REPORT FROM THE PROGRAM ON THE SURGICAL CONTROL OF THE HYPERLIPIDEMIAS (POSCH) [J].
BUCHWALD, H ;
CAMPOS, CT ;
BOEN, JR ;
NGUYEN, PA ;
WILLIAMS, SE .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1995, 26 (02) :351-357
[4]   Cholesterol reduction and stroke occurrence: An overview of randomized clinical trials [J].
Di Mascio, R ;
Marchioli, R ;
Tognoni, G .
CEREBROVASCULAR DISEASES, 2000, 10 (02) :85-92
[5]   Are drugs within a class interchangeable? [J].
Furberg, CD ;
Herrington, DM ;
Psaty, BM .
LANCET, 1999, 354 (9185) :1202-1204
[6]   Treatment and secondary prevention of stroke: evidence, costs, and effects on individuals and populations [J].
Hankey, GJ ;
Warlow, CI .
LANCET, 1999, 354 (9188) :1457-1463
[7]   Does cholesterol lowering prevent stroke? [J].
Henry, RY ;
Kendall, MJ .
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 1998, 23 (05) :337-344
[8]   Primary and secondary prevention of coronary artery disease: Trials of lipid lowering with statins [J].
Pearson, TA .
AMERICAN JOURNAL OF CARDIOLOGY, 1998, 82 (10A) :28S-30S
[9]  
Qizilbash N, 1995, LANCET, V346, P1647
[10]   Antiatherothrombotic properties of statins - Implications for cardiovascular event reduction [J].
Rosenson, RS ;
Tangney, CC .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 279 (20) :1643-1650